Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.

Cancer chemotherapy and pharmacology - 1 Apr 2015

Panoilia Eirini, Schindler Emilie, Samantas Epaminontas, Aravantinos Gerasimos, Kalofonos Haralabos P, Christodoulou Christos, Patrinos George P, Friberg Lena E, Sivolapenko Gregory

Abstract excerpt

PURPOSE: To characterize the population pharmacokinetics of bevacizumab, its binding properties to VEGF165 and the effect of demographic data and VEGF-A polymorphisms on the interplay between bevacizumab serum pharmacokinetics and VEGF165 serum concentrations in patients with colorectal cancer stage IV. METHODS: Bevacizumab and VEGF165 data were collected from 19 adult patients with metastatic colorectal cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Bevacizumab

Share to Colorectal Neoplasms

Share to Drug Administration Schedule

Share to Models, Biological

Share to Vascular Endothelial Growth Factor A

Source

Open in PubMed Open full text

Identifiers

PMID: 25687989
DOI: 10.1007/s00280-015-2701-3
PMCID: PMC4365273

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.PMID 25687989Read ↗

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.Semantic proximity Read ↗

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.Semantic proximity Read ↗

Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.Semantic proximity Read ↗

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.Semantic proximity Read ↗

Evaluation of ABC gene polymorphisms on the pharmacokinetics and pharmacodynamics of capecitabine in colorectal patients: Implications for dosing recommendations.Semantic proximity Read ↗

Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment.Semantic proximity Read ↗

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.Semantic proximity Read ↗

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.Semantic proximity Read ↗

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.Semantic proximity Read ↗

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.Semantic proximity Read ↗

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.